This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1
- Acute Administration of Haloperidol Does Not Influence 123I-FP-CIT Binding to the Dopamine Transporter
- (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study
- Assessing the Optimal Time Point for the Measurement of Extrastriatal Serotonin Transporter Binding with 123I-FP-CIT SPECT in Healthy, Male Subjects
- Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study
- SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0
- Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies
- Validation of a Standardized Normalization Template for Statistical Parametric Mapping Analysis of 123I-FP-CIT Images
- Quantification of Striatal Dopamine Transporters with 123I-FP-CIT SPECT Is Influenced by the Selective Serotonin Reuptake Inhibitor Paroxetine: A Double-Blind, Placebo-Controlled, Crossover Study in Healthy Control Subjects
- Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter
- Quantification of 123I-PE2I Binding to Dopamine Transporter with SPECT After Bolus and Bolus/Infusion
- [123I]FP-CIT SPECT findings in two patients with Hallervorden-Spatz disease with homozygous mutation in PANK2 gene
- Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease
- The harsh realities facing the use of SPECT imaging in monitoring disease progression in Parkinson's disease
- Dosimetry of the Dopamine Transporter Radioligand 18F-FPCIT in Human Subjects
- Investigating Dopaminergic Neurotransmission with 123I-FP-CIT SPECT: Comparability of Modern SPECT Systems